The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
remibrutinib · Powder
1 marketed package NDCs · 1 active manufacturer
Most dispensed: 25 mg · Tablet · #60 tablets/bottle
What changed in the last 90 days
Every detected change for remibrutinib, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
Same drug class
Other molecules FDA puts in Kinase Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Remibrutinib in shortage right now?
- No. FDA does not currently list Remibrutinib in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Remibrutinib?
- 2 companies have marketed Remibrutinib in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
- What does Remibrutinib cost?
- The typical pharmacy pays about $72.53 per unit, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.